Regeneron Pharmaceuticals (NASDAQ:REGN) will collaborate with Zai Lab Limited (NASDAQ:ZLAB)
to develop and commercialize REGN1979, a CD20xCD3 bispecific antibody,
in Greater China (mainland China, Hong Kong, Taiwan and Macau). The
partnership will start with a pivotal Phase 2 study in B-cell
non-Hodgkin lymphoma.
Under the terms of the agreement, Regeneron will
receive $30M upfront, up to $160M in milestones and a share of profits.
Zai Lab will contribute to global development costs for certain trials.
Regeneron will manufacture and supply.
Zai Lab hosted a conference call this morning at 8:00 am ET to discuss the partnership.
https://seekingalpha.com/news/3559219-regeneron-teams-up-zai-lab-to-commercialize-antibody-in-greater-china
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.